Envelope phospholipase OPG057 · SINGLE PROTEIN · Variola virus
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Envelope phospholipase OPG057 shows approved-linked disease relevance led by smallpox. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P33815. Start with smallpox, then reuse UniProt P33815 as the stable protein anchor across project notes and exports.
Start with smallpox, then reuse UniProt P33815 as the stable protein anchor across project notes and exports.
Envelope phospholipase OPG057 shows approved-linked disease relevance led by smallpox. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with smallpox because it currently carries approved-linked support. Linked drugs include TECOVIRIMAT, TECOVIRIMAT MONOHYDRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyEnvelope phospholipase OPG057
Review this target as Envelope phospholipase OPG057, mapped to UniProt P33815. Sequence length is 372 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Envelope phospholipase OPG057 as ChEMBL target CHEMBL5308522, mapped to UniProt P33815. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Envelope phospholipase OPG057 is the right protein anchor across sources, using UniProt P33815 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why smallpox is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Envelope phospholipase OPG057 |
| Target Type | SINGLE PROTEIN |
| Organism | Variola virus |
| UniProt | P33815 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Envelope phospholipase OPG057 |
| UniProt Accession | P33815 |
| Component Type | Protein |
| Sequence Length | 372 aa |
Envelope phospholipase OPG057
Review this target as Envelope phospholipase OPG057, mapped to UniProt P33815. Sequence length is 372 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Envelope phospholipase OPG057 shows approved-linked disease relevance led by smallpox. 5 more disease programs remain visible in the same review block.
Start review with smallpox because it currently carries approved-linked support. Linked drugs include TECOVIRIMAT, TECOVIRIMAT MONOHYDRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.